Tarnished HALO For Targacept/AstraZeneca Schizophrenia Drug
This article was originally published in The Pink Sheet Daily
Executive Summary
Partners halt development of AZD3480 in schizophrenia after Phase II failure, but will wait for ADHD trial before deciding the fate of the compound.
You may also be interested in...
Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors
Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.
Targacept’s Alzheimer’s Bid With AstraZeneca Is Iffy, But NNR Could Lure Other Suitors
Roche takeover of recent “Memory” – albeit an easy grab – may bode well for leader in the experimental space.
Roche Snaps Up Memory, Gains CNS Drugs
Swiss drugmaker gains partnered compounds in Alzheimer’s and schizophrenia via $50 million deal.